Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2018 | Improving the activity of BH3 mimetic venetoclax: a case study

Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Monash University, Melbourne, Australia, discusses clinical trials investigating the effect of BH3 mimetic drugs, such as venetoclax, on acute myeloid leukemia (AML). Current studies are trying to improve the activity of venetoclax in combination with low-dose chemotherapy and hypomethylating agents in patients with poor risk FLT3, DNMT3A or IDH mutations to produce a longer, more sustainable remission. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.